The human microbiome, composed of trillions of microorganisms living in the gut, skin, and other body sites, plays a vital role in regulating immunity. A balanced microbiome strengthens immune responses, protects against pathogens, and reduces the risk of autoimmune and inflammatory diseases. Disruption of microbial balance, known as dysbiosis, is linked to conditions such as allergies, obesity, diabetes, and even cancer. Advances in microbiome research are leading to new probiotics, prebiotics, and microbiota-based therapies that enhance immune health and overall well-being.
Market Analysis: In 2025, the global microbiome and immunity market—which includes probiotics, microbiome therapeutics, diagnostics, and dietary supplements—is valued at approximately USD 6.8 billion. Growing consumer interest in gut health, coupled with advances in microbiome-based drug development, is expected to drive the market to USD 12.1 billion by 2030, with a CAGR of 11.5%. North America leads due to strong R&D and commercial adoption, while Asia-Pacific shows the fastest growth fueled by rising demand for functional foods and preventive healthcare solutions.
